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The key goal and main challenge of radiation therapy is the elimination of
tumors without any concurring damages of the surrounding healthy tissues
and organs. Radiation doses required to achieve sufficient cancer-cell kill
exceed in most clinical situations the dose that can be tolerated by the
healthy tissues, especially when large parts of the affected organ are irradi-
ated. High-precision radiation oncology aims at optimizing tumor cover-
age, while sparing normal tissues. Medical imaging during the preparation
phase, as well as in the treatment room for localization of the tumor and
directing the beam, referred to as image-guided radiotherapy (IGRT), is
the cornerstone of precision radiation oncology. Sophisticated high-resolu-
tion real-time IGRT using X-rays, computer tomography, magnetic reso-
nance imaging, or ultrasound, enables delivery of high radiation doses to
tumors without significant damage of healthy organs. IGRT is the most
convincing success story of radiation oncology over the last decades, and it
remains a major driving force of innovation, contributing to the develop-
ment of personalized oncology, for example, through the use of real-time
imaging biomarkers for individualized dose delivery.
Abbreviations
ART, response-adaptive radiotherapy; CBCT, cone-beam CT; CT, computer tomography; CTV, clinical target volume; GTV, gross tumor
volume; HNSCC, head-and-neck squamous cell carcinoma; IGRT, image-guided radiotherapy; IMRT, intensity-modulated radiation therapy;
linac, linear accelerator; MRI, magnetic resonance imaging; NKI, Netherland Cancer Institute; NSCLC, non-small-cell lung cancer; OAR,
organs at risk; OMD, oligometastatic disease; PET, positron emission tomography; PTV, planning target volume; RT, radiotherapy; SABR,
stereotactic ablative radiotherapy; SBRT, stereotactic body radiotherapy; SMART, stereotactic MR-guided adaptive radiation therapy; TRUS,
trans-rectal ultrasound; VMAT, volumetric-modulated arc therapy.
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1. Introduction
Radiation therapy aims for destroying the tumor with-
out damaging the surrounding normal tissues and
organs. Radiation doses required to achieve sufficient
cell kill in cancers exceed in most clinical situations the
dose that is tolerated by the normal tissues, especially
when large parts of the respective organ are being irra-
diated. This delicate balance between the radiation
dose–response relationship for tumor cell kill and
probability of normal tissue toxicity represents the
core principle and also the main challenge of radiation
oncology. Coverage of the tumor and sparing of nor-
mal tissues is the main optimization approach of high-
precision radiation oncology. In the late 19th century,
X-ray radiation was limited in energy and, therefore,
radiation therapy was limited to superficial neoplasms
such as of the skin. By contrast, high-energy radiation
beams used nowadays target with geometric precision
of millimeters virtually all tumors in the body includ-
ing brain, lung, breast, prostate, etc. For the treatment
of superficial tumors, the radiation beam can be
adjusted by eye to ensure full coverage of the tumor
and sparing of critical adjacent organs. However, med-
ical imaging is required for the precise adjustment of
radiation beams targeting tumors that are located in
the inner of the body of the patient. Medical imaging
for tumor localization during the preparation phase, as
well as in the treatment room for localization of the
tumor and directing the beam is referred to as image-
guided radiotherapy (IGRT). Sophisticated high-reso-
lution and real-time IGRT using X-rays, computer
tomography (CT), magnetic resonance imaging (MRI),
or ultrasound constitutes the basis of modern radiation
oncology, enabling the delivery of high radiation doses
to tumors without significant damage of healthy
organs. IGRT is the most convincing success story of
radiation oncology over the last decades. And it
remains a major driving force of innovation, contribut-
ing to personalized oncology through the development
and implementation of real-time imaging biomarkers
for individualized and real-time control of dose deliv-
ery. In this review article, we describe current develop-
ments in IGRT and comment on avenues for further
research. CT-based IGRT, high-precision image-guided
stereotactic ablative radiation oncology, image-guided
brachytherapy in gynecological and prostate cancers,
molecular imaging with positron emission tomography
(PET), and 0.35T hybrid- and high-field MR-linear
accelerator (linac) are discussed. In addition, we review
quantitative imaging for response-adaptive radiation
oncology.
2. CT-based IGRT
Up to the beginning of this century, most image guid-
ance was based on 2D imaging, that is, MV imaging
using the treatment beam in combination with a spe-
cialized image detector [1] or kV imaging using one or
two independent kV sources and standard X-ray image
detector [2]. As 2D imaging only allows identification
of rigid and radio-opaque objects (bones, implanted
markers), there is an obvious benefit of integrating 3D
imaging with the treatment machine, such that the
tumor and surrounding organs at risk (OAR) can be
localized prior to each treatment fraction. This allows
the treatment then to be adapted to compensate for
changes in the absolute and relative position of target
and surrounding OAR. Even though acquisition of 3D
images is somewhat slower, its interpretation is easier,
faster, and more accurate than of planar imaging, and
therefore, volumetric imaging has become the de facto
standard of image guidance in current radiotherapy
(RT). In RT, as well as in surgery, standard diagnostic
CTs were first utilized for guidance, either placed on
rails or with robotic movement of the patient from the
treatment position into the imaging position. Later,
cone-beam CT (CBCT) was used, which features a
more compact design. This allows CBCT to be inte-
grated with the gantry of a treatment machine, or be
placed on an independent robot. This section presents
a roughly chronological overview of these technolo-
gies, listing some of their advantages and disadvan-
tages, and describing some clinical applications.
The first reported integration of diagnostic CT sys-
tems in the RT treatment room was reported in New
York and Houston [3]. The advantage of these systems
is that they provide diagnostic image quality, but they
have the major disadvantage that the CT scanner can-
not share the same isocenter as the treatment
machines. This means that one must move the patient
between devices, and correct for mechanical instability
and patient motion in the transition, or only perform
relative localization, with the absolute localization pro-
vided by other (e.g., planar) imaging on the treatment
machine. The advantage of using a readily available
CT device is also a disadvantage, because they suffer
from a lack of integrated software for image guidance,
making workflows less efficient.
Some of the clinical applications of in-room CT
include studies on head-and-neck deformation in
Houston [4], applications in proton and particle ther-
apy [5], and integration with the Cyberknife [6].
Modern CT developments such as dual-energy CT
can be readily integrated in the in-room CT approach
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with this approach, making it an attractive solution
for dose calculation in particle therapy.
Tomotherapy was proposed by Mackie et al. in 1992
[7]. It involves mounting a linac on a CT scanner like
gantry, using so that the same radiation source for treat-
ment and imaging. The system utilizes the unique proper-
ties of a gridded xenon filled detector to achieve a very
high quantum efficiency at the used high photon energies
for imaging, reducing soft tissue contrast. High energies
are required because the 6 MV treatment source cannot
go down to diagnostic energies but operates around
300 kV. The obvious advantage of tomotherapy is that it
requires only a single source. As imaging at high energy
is insensitive to metal artifacts, tomotherapy is ideally
suited to treat patients with metal implants. A major dis-
advantage is that the detector is single slice, therefore, the
amount of time required to scan a region of interest is
directly proportional to its length with an imaging time
of about 6 s per slice. Clinical application of tomother-
apy is quite broad, ranging from prostate to head and
neck RT. Recent developments include the addition of
tumor tracking to the device [8].
Integration of CBCT on an accelerator (gantry-based
CBCT) was first proposed by Jaffray and Wong around
1997; the first prototypes were constructed in Beaumont
and Toronto prior to the year 2000 in collaboration with
Elekta Fig. 1 [9]. The early development of high-speed
3D and 4D image reconstruction software, as well as
practical workflow software at the Netherland Cancer
Institute (NKI), allowed the system to be put into clinical
use quite early [10]. NKI commenced routine clinical use
with in-house software in 2004 [11]. The first product was
released by Elekta in 2005, with software developed by
NKI, with Varian following a few years later.
The main advantage of CBCT-IGRT is its integra-
tion with the treatment machine, providing a cali-
brated isocenter position (even though the isocenter
coincidence must verified regularly [12]. This means
that no patient or table motion is required between
imaging and treatment. Current CBCT-IGRT systems
provide integrated software solutions focusing on
localization of tumor and/or OAR.
Since 2009, 4D CBCT imaging is available commer-
cially facilitating visualization of tumors that move
under respiratory motion without motion blurring. This
is a requirement for accurate image guidance of mobile
tumors moving over 1 cm pp [13]. Since 2012, CBCT
imaging during volumetric arc therapy (VMAT) deliv-
ery is available [14], providing an efficient method of
verification imaging during hypofractionated delivery,
that is, to check whether the planned tumor position is
actually achieved during therapy. Disadvantages of
CBCT are (a) that image acquisition is slow on an open
gantry due to legal gantry speed limitation (Interna-
tional Electrotechnical Commission limit is 1RPM), (b)
the image quality of CBCT is somewhat poorer than
fan-beam CT due to the large amount of X-ray scatter
emanating from the patient (which is software corrected
or rejected by a scatter grid). But the main limitation of
CBCT is a poor image quality in regions of the body
with much internal motion due to respiration and gas,
causing blurring of soft tissue interfaces.
Currently, CBCT-IGRT is the most common form
of image guidance used in the clinic; millions of
patients have been treated with such systems. CBCT-
IGRT allows shrinking of safety margin, for example,
reducing rectal toxicity in the treatment of prostate
cancer and enabling frameless radiosurgery of brain
Fig. 1. (A) Initial CBCT prototype by Jaffray et al. (B) Modern integrated CBCT system. (C) Software system for image reconstruction and
analysis illustrating a workflow-based design.
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and lung tumors. Integrated with proton therapy
machines, CBCT is particularly well suited for treat-
ment of tumors in the brain, head and neck, lung,
breast, or extremities. CBCT is very well suited for
tumors in the brain, head and neck, lung, breast, and
extremities, but less so for abdominal organs due to
motion. In combination with breath-hold, CBCT guid-
ance for abdominal organs is feasible.
The efficacy of CBCT-IGRT is expected to increase
further through better reconstruction algorithms (itera-
tive reconstruction now available in Varian software).
Integration of efficient scatter grids [15], integration on
ring-based gantries with very good mechanical stability
and faster rotation [16]. Faster and lower dose image
acquisition (image gently) especially for pediatric
patients receiving proton therapy [17].
Robotic CBCT place the kV source and detector on
a robotic device that can be attached to the ceiling [18]
or to the patient table [19]. These systems are mainly
utilized for particle therapy because they allow scan-
ning motion independent of gantry rotation (which
can be slow in particle therapy) and for RT systems
that lacks a gantry. Advantages are that these are uni-
versal systems that can be used in multiple disciplines.
Robotic CBCT systems allow faster scanning than
open gantry systems due to their smaller dimensions.
Also robotic systems allow complex scanning geome-
tries (offset and helical) enabling larger fields of view.
Disadvantages of robotic systems are cost, the poten-
tial for collision, and the increased amount of scatter
due to smaller distances of patient to detector.
Overall, CT-based guidance is the current standard
for image guidance. It is very well suited for treatment
of tumors in the brain, head and neck, lung, breast, or
extremities, but less so for abdominal organs due to
motion blurring (CBCT) or motion distortion (CT).
Often CT imaging dose is mentioned as a major disad-
vantage, but the use of acquisition protocols that are
consistent with the image guidance task, the imaging
dose can be reduced compared to diagnostic tasks and
tends to be insignificant compared to the treatment
dose, scatter, and leakage. The increased accuracy of
image guidance, however, requires further optimization
of all RT processes [20].
3. MR-based IGRT
3.1. The 0.35T hybrid MR-linac
In 2012, ViewRay (ViewRay Inc., Cleveland, OH,
USA) introduced an integrated magnetic resonance-
guided RT system (MRIdian). This system combined a
0.35T MRI with a robotic three-headed 60Co RT sys-
tem [21]. In 2017, the RT part of the system was
replaced by a 6 MV linac.
The MRIdian linac system uses a split magnet MRI
system, combined with a rotating gantry that houses
the linac Fig. 2. The double-focused and double-
stacked multileaf collimator leads to a very sharp
beam penumbra, making it optimally suited for stereo-
tactic treatments as well. In addition, the system comes
with a software system that enables the immediate and
rapid use of the actual anatomical imaging into an
adapted treatment plan. MR imaging during the beam
delivery allows for additional control and gated deliv-
ery. In January 2014, the first patient was treated on
the MRidian Cobalt system at Washington University,
St. Louis, and later that year, the first adaptive treat-
ments were delivered [22]. A small number of 60Co sys-
tems have been installed, and currently, around 20
MRIdian linac systems are operational worldwide.
Fig. 2. ViewRay system consists of 0.35T split magnet MRI system (A), with a rotating gantry housing a 6 MV linac (B), equipped with 138-
leaf double-focused double-stacked multileaf collimator (C).
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The use of MRI guidance on the linac offers various
benefits. First of all, the improved soft tissue imaging
over CBCT scanning obviates the need for implanted
markers. A clear view of the tumor and surrounding
organs risk makes it possible to use smaller safety
margins. Secondly, the ViewRay software makes it
possible to adapt the treatment plan to the anatomy of
the day. This avoids high doses to critical structures in
the vicinity of the tumor and an improved coverage of
the tumor. The third major benefit is that for the first
time in the history of RT, the tumor and organs
around it can be visualized continuously during the
delivery of the beam. This enables a more precise
tracking of the delivered dose, but also the ability to
shut down the beam immediately if unfavorable condi-
tions occur during the treatment (e.g., passing of rectal
gas during irradiation for prostate cancer). The group
at VUmc in Amsterdam developed a system that
enables the patient to see the MR images with indi-
cated tumor during treatment and use it for the
breath-hold gated delivery [23]. These benefits are
anticipated to result in improved tumor control and
reduced side effects. The time per treatment fraction is
significantly longer compared to conventional treat-
ments, especially when daily adaptation is performed
[24]. Therefore, daily treatment plan adaptation is
often reserved for hypofractionated treatments. Daily
plan adaptation leads to a different workflow and
involvement of radiation oncologists and medical
physicists with every treatment session. Some centers
have dedicated radiation oncologist and physicist con-
tinuously present at the machine.
Although the MRIdian system can be used for virtu-
ally all indications, stereotactic MR-guided adaptive
radiation therapy (SMART) has primarily been used
for moving tumors in thorax and upper abdomen and
in the pelvis. To reduce the time needed for contour-
ing, an approach has been developed where only the
OAR in the region in the first centimeters around the
tumor are recontoured [25].
In pancreatic cancer, SMART leads to improved
target coverage and better sparing of OAR [26,27]. An
evaluation of 180 adaptive treatment fractions showed
that the percentage of plan meeting all dose con-
straints increased from 44% to 83% [26]. The benefit
of daily plan adaptation was observed in about half of
the fractions and mainly when the distance between
tumor and OAR was 3 mm or less [26]. A nonran-
domized comparison of patients with inoperable pan-
creatic tumors treated with SMART to higher
compared to standard doses showed improved local
control and improved overall survival [28], indicating
that this approach holds many promises.
In patients with central [29] and ultracentral [30]
lung tumors, at increased risk for toxicity, plan adap-
tation resulted in fewer violations of treatment plan-
ning constraints. In over 90% of fractions, the
optimized treatment plan was chosen and the coverage
of the tumor was improved, while excessive doses to
surrounding structures where avoided. This widens the
therapeutic window of stereotactic treatments for this
group of lung cancer patients.
There are many other indications where SMART
has already shown to be of benefit. Examples are liver
tumors, adrenal metastases, kidney tumors, and pros-
tate tumors. To generate clinical evidence, a number
of prospective studies have been initiated.
3.2. High-field MR-linac
Using active magnetic shielding the magnetic field just
outside an MRI can be minimized, allowing the posi-
tioning of a linac gantry in this zone, fully decoupling
the two systems Fig. 3. This makes it possible to com-
bine a high-field MRI with a regular RT accelerator,
with the accelerator rotating around the MRI cryostat.
Such a system is capable to deliver diagnostic quality
1.5T MR images, while the accelerator dynamically
delivers its dose [31,32]. The radiation beam has to
pass through the MRI cryostat. This results in some
beam attenuation and an isocenter source distance of
about 1.45 m. Within the cryostat, a radiation trans-
parent window has to be created without supercon-
ducting wires. To let the beam pass also the gradient
coil has been split. This window limits the caudal cra-
nial field size to about 22 cm. Wider gaps will reduce
the image quality of the MRI. Using this design, the
Elekta Unity can execute diagnostic examcards
designed for Philips 1.5 T MR radiology systems,
while having stereotactic precision RT dose delivery
[33]. The Unity system is by its diagnostic quality
1.5 T MRI prepared for functional imaging during
treatment delivery.
Dose deposition is thus performed with the patient
inside the 1.5 T magnetic field. The magnetic field
changes the dose deposition by influencing the tracks
of the secondary electrons. Those electrons take curved
paths, resulting in a slightly shifted beam profile and
the electron return effect at tissue–air interfaces [34].
These phenomena are well investigated and relatively
easy to handle, but requires that the dose engine of
the treatment planning system has been based on
Monte Carlo code. This is to assure that the physics
are well taken into account.
The online MR images allow treatment optimization
at a daily base. The online MRI is being registered to
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the simulation CT to provide the Hounsfield patient
data. The online image is being registered to the simu-
lation MRI to obtain the tumor and OAR contours,
contours are adjusted if needed. With this information,
a new treatment plan is being created [35]. This online
adaptive procedure not only deals with translations,
but also with rotations, deformations, and tumor
regression, making table translations and rotations
obsolete.
The MRI offers the possibility to visualize the real-
time 3D anatomy of the patient at the exact moment
of irradiation. Making the MRI that fast that anatomy
can be followed on a subsecond time scale is currently
investigated in several institutes. It will be clear that
this real-time visualization also allows real-time dose
accumulation and thus real-time dose optimization.
The blue-sky will be that a patient anatomy is being
followed in real time, while the dose delivery is being
optimized continuously, making the treatments robotic
self-navigating optimizations.
Online MRI also allows that the treatment proce-
dure may become an interventional one. MRI-guided
modifications of the anatomy for OAR sparing, like
temporarily spacers between rectum wall and prostate,
must be evaluated.
To generate clinical evidence an international con-
sortium was founded, the R-IDEAL framework was
developed and all groups are collaborating in the mul-
tiple outcome evaluation of RT (Momentum) database
[36]. The objective of this database is to generate clini-
cal and imaging data to evaluate treatment outcome
and to act as a repository for evaluation and training.
Clinical trials currently explore the benefits of MR-
guided RT in patients with cancers of the liver, esoph-
agus, bladder, brain, lung, rectum, head and neck,
prostate and breast as well as in oligometastatic dis-
ease (OMD) [37–46].
High-field MR-linacs have the potential to become
the next-generation RT standard. The concept of see-
ing what you treat is extremely strong. Such a develop-
ment would transform RT toward an interventional
radiology procedure, making wide imaging knowledge
a prerequisite. Stereotactic precision dose painting
according to actual tumor presence, tumor characteris-
tics, and OAR sensitivity will become the new stan-
dard, driving RT toward concentration in broader and
larger departments.
4. Molecular imaging with positron
emission tomography in radiation
oncology
With the routine use of intensity-modulated radiation
therapy (IMRT) or VMAT allowing highly conformed
dose distributions, there is an increasing need for refin-
ing the delineation of the gross tumor volumes (GTV).
Molecular imaging, also known as biological imaging
or functional imaging, is the use of noninvasive imag-
ing techniques that enable the visualization of various
biological pathways and physiological characteristics
of tumors and/or normal tissues. It mainly refers (but
is not limited to) PET, which, with the use of various
Fig. 3. (A) Schematic design and (B) Elekta Unity system.
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tracers, offers the opportunity to improve diagnostic
accuracy and to integrate tumor biology mainly related
to the assessment of tumor cell density, tumor hypox-
ia, and tumor proliferation into the treatment planning
process [47]. Furthermore, with the apprehension of
the heterogeneity in tumor biology with molecular
imaging, growing evidence has been collected over the
years to support the concept of dose escalation/dose
redistribution using a planned heterogeneous dose pre-
scription, the so-called ‘dose painting’ approach. Vali-
dation trials are ongoing, and in the coming years, we
expect to position the dose painting approach in the
armamentarium for the treatment of patients.
In the following PET image acquisition, reconstruc-
tion and segmentation with special consideration for
radiation oncology are discussed. The usage of PET
for target volume selection and delineation has much
stronger requirements in terms of image quality in
comparison with diagnostic PET imaging. PET has a
rather low spatial resolution in the order of 5 mm,
and a high level of noise due to the rather low number
of emitted and detected photons as a consequence of
the limited activity that can be administered to
patients for obvious radioprotective reasons. To cir-
cumvent these limitations, PET images are typically
acquired in 3D mode, are corrected for scatter, attenu-
ation, random events, and dead time, and, if available,
acquired using time-of-flight measurements, or new
crystal scintillators and silicon photomultipliers to
improve both time and space resolution [48]. PET
image reconstruction is routinely done using iterative
algorithms, and postreconstruction processing such as
the use of denoising, deblurring, or edge-preserving fil-
ters can be used to further enhance image quality [49].
Accurate delineation of the tumor volume and shape
from PET images remains an open challenge. Different
delineation methods, validated for specific tumor sites,
and to various extents, on phantoms, synthetic images,
other imaging modalities like CT, or ground truth
have been proposed [50].
Clinical evidence for the use of PET for target vol-
ume delineation has been demonstrated for FDG-PET
mainly in head and neck and in lung cancer. In locally
advanced head and neck squamous cell carcinoma
(HNSCC), FDG-PET-based GTV definition has been
shown to be more accurately related to the macro-
scopic tumor specimen. Its use for planning purposes
was associated with a significant reduction of the clini-
cal target volume (CTV) and planning target volume
(PTV), as well as with a sparing of critical normal tis-
sues when IMRT treatment was used [51]. In non-
small-cell lung cancer (NSCLC), the use of FDG-PET
has been shown to change the delineation of the
primary tumor GTV by discriminating tumor tissue
from atelectasis or necrosis and to improve the delin-
eation of positive mediastinal lymph nodes [52]. Such
volume modifications also translated into modification
of the dose distribution. Methodological issues related
to breathing motion have been identified and four-di-
mensional PET acquisition has been shown to improve
tumor visualization and accuracy of volume recon-
struction [53]. In esophageal carcinoma, no definite
data support the use of FDG-PET for the primary
tumor delineation, but it could have benefit in individ-
ualizing positive lymph nodes outside of the medi-
astinum [54]. In cervix carcinoma, FDG-PET has been
shown to be very specific for the selection and delin-
eation of para-aortic lymph nodes, but has not shown
any benefit for the primary tumor delineation [55]. In
the brain, owing the high physiological FDG uptake,
other PET tracers have been studied, and 11C-methion-
ine has been shown to have an added value in delin-
eating recurrent tumor, glioma, or meningioma [54].
Last in prostate carcinoma, 68gallium- or 18F-PSMA
has shown promising results for the management of
recurrent disease and ongoing studies indicate that
these tracers may outperform conventional imaging
[56].
Radiation dose painting, that is, the prescription
and delivery of a nonuniform dose to the CTV, is a
different paradigm in radiation therapy [57]. The basic
idea is to replace, completely or in part, the morpho-
logically, or anatomically defined target volumes with
a map of the spatial distribution of a specific tumor
phenotype that is hypothesized or has been shown to
be related to local tumor control after RT Fig. 4. A
dose prescription function is then used to transform
this map into a map of prescribed doses that can be
used as input to an inverse planning optimizer, either
to increase or to redistribute the prescribed dose.
The current interest in dose painting focuses mainly
on three evidence-based causes of RT failure in the
clinic: tumor burden or tumor cell density, tumor cell
proliferation, and tumor hypoxia. For tumor burden,
a prospective randomized phase II dose painting and
dose escalation study was recently reported in locally
advanced HNSCC, whereby the prescribed dose was
increased up to 81 Gy on the FDG-PET avid area.
This study showed a statistically significant improve-
ment in local control (from 75% after 69 Gy to 88%
after dose painting at 2 years) without long-term
mucosal ulceration providing that the 80-Gy isodose
volume does not exceed 1.75 cm3 [58]. Tumor hypoxia,
which can be imaged using various 18F-labeled PET
tracers, has been observed in a large variety of human
tumors, and its presence was correlated to local relapse
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after RT in head and neck carcinoma [59]. In proof-
of-concept planning studies, it has been calculated that
a dose increase to the tumor hypoxic area by 15–20%
could substantially increase the control probability
without affecting normal tissue toxicity (see review in
[51]. Conversely, it has also been shown that in
patients with HPV-positive oropharyngeal carcinoma,
a reduction of the prescribed radiation dose of 10 Gy
to the lymph nodes in patients showing a resolution of
hypoxia after 1 week of treatment was a safe approach
[60]. Regarding cell proliferation, the fluorinated thy-
midine analog 18FLT has been used in human tumors
to define subtarget volumes that might get an addi-
tional radiation dose level (see review in [51]. However,
in the absence of direct clinical evidence for an associ-
ation between these regions and a subsequent local
treatment failure, the biological rationale for this boost
strategy is still not completely clear, and further data





Ablating small targets with focal radiation has been
practiced successfully since the 1950s for intracranial
lesions, making radiosurgery (stereotactic radiosurgery)
a noninvasive treatment option for functional and vas-
cular disorders, benign and malignant tumors. How-
ever, multiple technological advances were required to
transfer this concept from the neurocranium to targets
located in the body: extracranial stereotactic RT,
today called stereotactic body RT (SBRT), or stereo-
tactic ablative RT (SABR), has been developed and
first clinically introduced at the Karolinska Hospital in
Sweden in 1994 [61] and shortly thereafter been pio-
neered by Japanese [62] and German [63,64] RT cen-
ters. SBRT was characterized by rigid patient
positioning and immobilization in a stereotactic body
frame, control of breathing-induced target motion,
conformal treatment planning by noncoplanar treat-
ment techniques, inhomogeneous dose distributions in
the target and dose delivery in few fractions of high
single fraction doses Fig. 5.
Initial clinical experiences and early prospective tri-
als of SBRT were made using conventional linacs with
and the stereotactic body frame was the most relevant
SBRT-specific hardware innovation. This frame aimed
to establish a system of external coordinates for locat-
ing the target volume at simulation and subsequently
for targeting at the time of treatment. The replacement
of this external stereotactic body frame by in-room
imaging has been the most relevant advancement of
SBRT. In-room imaging allows immediate visualiza-
tion of the tumor before and during RT delivery
through several approaches: stereoscopic X-ray imag-
ing; CBCT, and integrated MRI. Image guidance with
online adjustment of the isocenter position, or online
adaptive re-optimization of the RT plan, improved the
accuracy of SBRT through the compensation of inter-
fractional and intrafractional variations in target and
organ-at-risk position, shape, and volume, thereby
minimizing unintentional exposure of normal tissue
with ablative radiation doses. IGRT addresses both
nonperiodical and periodical motion, in particular
Fig. 4. PSMA-PET-based focal boosting in prostate cancer. (A) Axial PSMA-PET-CT slice showing the contours of the prostate (red), GTV
(cyan), rectum (brown), and the 50 Gy isodose (5 fractions of 10 Gy; marine blue). (B) Corresponding CT slice with color wash isodose
curve showing conformal dose shaping to the prostate (clinical tumor volume) treated to 35 Gy in five fractions of 7 Gy and intraprostatic
tumor (GTV) with sparing of the rectum and urethra. The intraprostatic lesion (cT1c, Gleason 3 + 4 = 7, iPSA = 16.6 ngmL1) is located in
the left transition zone. The patient participated into the multicenter prospective phase II hypo-FLAME study (NCT02853110, ClinicalTria
ls.gov).
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breathing-induced motion in the thorax and upper
abdomen. Further advances, among many others,
enabled more accurate dose calculation and improved
dose conformity with simultaneously rapid treatment
delivery by dynamic intensity-modulated RT.
It is important that these technological advances not
only improved accuracy and therefore the safety and
efficacy profile of SBRT, but also streamlined the pro-
cess of SBRT planning and delivery. Improved accu-
racy combined with a reliable and efficient SBRT
process was cornerstones for implementation of SBRT
outside of specialized centers and outside of prospec-
tive clinical trials. Today, SBRT is therefore routinely
practiced in the majority of RT centers [65]. In this
section, the clinical evidence-based rational for the use
of SBRT will be summarized using two clinical exam-
ples: early-stage NSCLC and OMD.
Traditionally, surgical lobectomy has been the only
evidence-based treatment option for early stage
NSCLC offering a high probability of cure. RT has
been indicated only in medically inoperable patients
because treatment failure was observed in the majority
of the patients. This is based on the observation that
RT delivered in conventional fractionation with doses
of about 60 Gy fails to achieve a high probability of
local tumor control. Modeling has suggested that
much higher radiation doses are necessary for eradica-
tion of NSCLC [66], and such doses are beyond nor-
mal tissue tolerance, if delivered to large volumes
using conventional RT techniques. The accuracy of
SBRT allowed for focal treatment with escalated and
sufficiently high irradiation doses beyond 100 Gy bio-
logically equivalent dose [67], which translated into
long-term local tumor control of 90% and improved
overall survival. High rates of local tumor control
combined with a favorable safety profile have been
consistently demonstrated in prospective [68] and ret-
rospective studies. Randomized controlled trials com-
paring conventionally fractionated RT with SBRT
confirmed the superiority of SBRT [69,70] and popula-
tion-based studies demonstrated that implementation
of SBRT allowed treatment of more patients with
curative intent and thereby improved overall survival
[71]. ESMO and NCCN guidelines therefore recom-
mend SBRT as the treatment of choice for patients
with inoperable stage I NSCLC (www.nccn.org,
www.esmo.org). Initial results further indicate that
SBRT may achieve similar or noninferior results [72]
compared to surgical treatment of stage I NSCLC,
however, prospective evidence is required to conform
this hypothesis. Currently, clinical trials are addressing
the value of biomarkers for early response assessment
and the combination of SBRT with immune-check-
point inhibition to reduce the risk of regional and dis-
tant recurrences, despite the lack of phase I and phase
II data, three large randomized phase 3 trials are cur-
rently addressing this question.
Oligometastatic disease has been defined as an inter-
mediate state between early stage, where cure is the
goal of radical local treatment, and systemic metasta-
sized stage, where local and systemic therapy follows a
palliative goal [73]. Although the term ‘oligometas-
tases’ was coined and defined in 1995, surgical resec-
tion of solitary or limited metastases has been
performed for decades and has achieved long-term dis-
ease-free survival and overall survival for selected
patients. However, based on a systematic review of oli-
gometastatic NSCLC, surgical resection was the exclu-
sive local treatment modality until 2003 and the
predominant modality until 2007 [74], with RT used in
only very few patients. This is explained by the inabil-
ity of conventional RT to locally eradicate
A B C D
Fig. 5. Development of image guidance in SBRT. (A) External stereotactic coordinates of the stereotactic body frame, (B) in-room CT, (C)
integrated CBCT, (D) integrated MRI imaging.
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oligometastases with sufficient safety and efficacy.
Safety and efficacy of SBRT have been demonstrated
in both primary and metastatic disease indicating that
sufficiently high radiation doses can successfully steril-
ize metastases of histologies, which were previously
assumed as radioresistant [75]. For pulmonary
oligometastases of NSCLC, a matched pair analysis
reported identical outcome of SBRT and surgical
metastasectomy and similar promising results of SBRT
have been described for other frequent oligometastases
locations such as the liver, adrenal gland, bone metas-
tases, and lymph node metastases [76]. The favorable
therapeutic ratio combined with rapid adoption of
SBRT was key to validate the concept of local ablative
treatment for OMD in general. Until today, four ran-
domized controlled trials evaluated the value of local
ablative treatment of all macroscopic cancer sites in
addition to standard of care systemic therapy: three
randomized controlled trials reported improved overall
survival in lung cancer [77], colorectal cancer [78], and
in a disease agnostic setting [79],the fourth study was
underpowered for OS but reported a significantly
improved progression-free survival [80]. Whereas
radiofrequency ablation was the exclusive locally abla-
tive treatment modality in the earliest CLOCC trial 17
[81], SBRT was the exclusive locally ablative treatment
modality in two studies [79,80] and the most frequent
in the study by Gomez et al. [77]. As a consequence,
the current ESMO guideline for oligometastatic
NSCLC states that the ‘relative contribution of surgery
versus RT as local treatment modality has not been
established yet’ in OMD (https://www.esmo.org/guideli
nes/lung-and-chest-tumours).
Despite these progresses, there are many challenges
which need to be addressed by future clinical and tech-
nological research Fig. 6. SBRT is constantly
improved from a technical perspective to further
improve its therapeutic ratio, especially for anatomical
locations, such as the mediastinum or abdomen. Clini-
cally, SBRT is being explored in the curative setting
for example prostate and kidney cancer, as well as for
palliative treatments, such as treatment of painful
bony metastases [82–84]. Moreover, multimodal treat-
ment concepts are developed to combine SBRT with
modern targeted therapy and immunotherapy [85].
6. Image-guided brachytherapy
Brachytherapy is a RT modality that uses sealed
radioactive sources placed inside or in close proximity
to a tumor target. The clinical precondition for
brachytherapy applications is direct access to the
tumor and a limited size tumor volume (up to 50–
100 cm3). At present, the most common sites for
administration of brachytherapy are gynecologic and
prostate cancer. In image-guided brachytherapy, the
imaging is performed with the brachytherapy applica-
tor in place, and it is possible to accurately depict the
target in relation to the irradiator [86]. A stable rela-
tion between target and source of radiation makes it
possible to treat accurately without the setup uncer-
tainty margins needed in external beam RT. In gen-
eral, brachytherapy treats a given target to higher
doses, while involving less irradiation of normal tissue
as compared to external beam RT [87].
For gynecological cancer, during the last two dec-
ades significant developments were achieved in
brachytherapy through the integration of MRI for tar-
get definition [88]. The major conceptual innovation
was to introduce MRI for identification of a response-
adaptive target concept. The ICRU89 report [89] and
GEC ESTRO recommendations [90] have established a
common terminology for target volumes with different
risk of recurrence in locally advanced cervical cancer.
Further GEC ESTRO recommendations follow a simi-
lar approach in primary vaginal cancer [91]. The adap-
tive approach includes target volumes defined at time
of diagnosis and at the time of brachytherapy. Target
volumes are defined at diagnosis:
Fig. 6. Median volumes and mean doses (D90 for adaptive CTV-
THR, D98 for adaptive CTV-TIR and GTV-Tres) for cervix cancer
(unpublished data from the EMBRACE I and II studies). In
EMBRACE II, the median volume of GTV-Tinit is 55 cm
3 (time of
diagnosis). The extent of the GTV-Tinit is reflected in the adaptive
CTV-TIR (time of brachytherapy), and this region received a median
near-minimum dose of 62 Gy in EMBRACE I. In good-responding
tumors, the dose at the border of the GTV-Tinit is 60–70 Gy, while
in poor-responding tumors, this region may receive doses similar to
the adaptive CTV-THR (e.g., around 80 Gy). Figure is modified from
[88] Fig. 6.
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 Initial GTV (GTV-Tinit): the primary GTV.
 Initial high-risk CTV (initial CTV-THR): the vol-
ume bearing the highest risk of recurrence; for
cervical cancer, this includes the whole cervix as
well as the GTV-Tinit.
 Initial low-risk target volume (initial CTV-TLR):
the compartments at risk of microscopic disease;
for cervical cancer, this is uterus, parametria,
(upper) vagina, and the anterior/posterior spaces
toward bladder and rectum.
An adaptive CTV takes into account the morphol-
ogy and topography of the GTV-Tinit as well as the
response to treatment. For cervical cancer, the adap-
tive target volumes are defined at the time of
brachytherapy. This is after delivery of external
chemoradiation of 40–50 Gy, which is assumed suffi-
cient to control microscopic disease. The adaptive tar-
get volumes are Fig. 6:
 Residual GTV (GTV-Tres): the residual gross
tumor.
 Adaptive high-risk CTV (adaptive CTV-THR):
the volume bearing the highest risk for recur-
rence; for cervical cancer, this includes the GTV-
Tres, the whole cervix, and adjacent residual
pathologic tissue, if present.
 Adaptive intermediate-risk CTV (adaptive CTV-
TIR): represents the GTV-Tinit as superimposed
on the topography at the time of brachytherapy,
together with a margin surrounding the adaptive
CTV-THR.
In prostate cancer, the advent of trans-rectal ultra-
sound (TRUS) and TRUS-guided brachytherapy [92]
had a profound and practice changing impact on the
management of prostate cancer and expected cancer
control outcomes [93] in patients with localized dis-
ease. This success was confirmed in subsequent ran-
domized trials [9], but has also highlighted a pressing
need to reduce the risk of urinary toxicity associated
with prostate brachytherapy [94], including obstructive
uropathy and pain.
One strategy currently under investigation is to inte-
grate MRI and/or PET images in order to identify
intraprostatic regions bearing dominant burden of can-
cer and considered at highest risk of recurrence [95].
The technical feasibility of such integration has been
demonstrated through both computational (MRI/
TRUS fusion) [96] and MRI-only methods [97], but a
clinical impact on patient outcomes remains to be
demonstrated.
In the following, the impact of image guidance on
treatment approaches in different types of diseases is
discussed. In cervix cancer, the introduction of image
guidance and response-adaptive target volumes had
major impact on the treatment approach [98]. Image-
guided brachytherapy takes into account both status
at diagnosis and treatment response, and the approach
has become highly individualized. The variable risk of
recurrence in the different target volumes is taken into
account through risk adaptive dose prescription. Typi-
cal total external beam and brachytherapy dose admin-
istration in cervix cancer is (EQD2 doses): 45–50 Gy
to regions with suspected microscopic spread at diag-
nosis (initial CTV-TLR), > 60 Gy to regions with sus-
pected microscopic spread defined at time of
brachytherapy (D98, adaptive CTV-TIR), > 85 Gy to
regions with major risk of (residual) macroscopic dis-
ease at brachytherapy (D90, adaptive CTV-THR),
> 90 Gy to regions with residual GTV at brachyther-
apy (D98, GTV-Tres) Fig. 6. The remarkable variation
in dose prescription across the different target volumes
is facilitated by the high brachytherapy dose gradient.
Image guidance and adaptation of application tech-
nique (addition of interstitial needles) in cervix cancer
have considerably improved the target dose coverage
while the overall irradiated volumes have been signifi-
cantly reduced [99]. The change of practice has
involved dose escalation in patients with advanced dis-
ease and poor response to external beam RT (e.g.,
through the use of interstitial needles [100], and dose
de-escalation in patients with limited disease and/or
favorable response [101].
In prostate cancer, the integration of images that
depict tumor within the prostate can facilitate a dose-
painted approach, whereby treatment can be de-inten-
sified in low-risk regions in order to reduce toxicity
while maintaining cancer control. Although still con-
sidered investigational, this strategy has gained
momentum and has been integrated in a prospective
phase III randomized clinical trial (NCT02960087). At
its extreme, this strategy also leads to the concept of
focal brachytherapy, which may be appropriate in
select patient subgroups and contexts.
The tolerance of tissue to the highly potent target
dose prescription (e.g., > 85–90 Gy) in both gyneco-
logical and prostate cancer brachytherapy is likely
explained by these considerable dose levels being
applied to only limited volumes. For example, in cer-
vix cancer, median volumes for GTV-Tres (median
D98 of 110 Gy) and adaptive CTV-THR (median D90
of 90 Gy) correspond to 6 cm3 and 29 cm3, respec-
tively Fig. 6.
The clinical evidence for improved outcome (disease
control and less morbidity) of image-guided
brachytherapy in cervix cancer has been demonstrated
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through mono-institutional reports and the large
EMBRACE multicenter studies: retroEMBRACE,
EMBRACE I, and EMBRACE II [102]. Retro-
EMBRACE demonstrated excellent local and pelvic
control with 3-year actuarial pelvic control of 96%,
89%, and 73% in stage IB, IIB, and IIIB disease,
respectively [103]. This is superior to reports of
chemoradiation [104,105] with an overall increase in
pelvic control of around 10%. The overall survival
was similar to results from randomized chemoradia-
tion trials [106] but around 12% better than large pop-
ulation-based cohorts treated with chemoradiation
[105,107]. At the same time, major morbidity was lim-
ited after image-guided adaptive RT (3–6% per organ)
[103,108–111].
In prostate brachytherapy, although clinical evidence
of improved disease control with prostate gland target-
ing under TRUS guidance is strong, high-level evi-
dence of decreased morbidity with an MRI-guided and
tumor-targeted approach is lacking. Ongoing random-
ized trials of focal brachytherapy boost to external
beam RT (NCT04100174), or dose-painted brachyther-
apy (NCT02960087) are expected to report in the com-
ing years.
In conclusion, the principles of image-guided and
response-adaptive image-guided brachytherapy have
the potential to improve outcomes in other cancers,
where definitive RT is delivered as a combination of
external beam RT, followed by a brachytherapy boost.
Such cancers include rectum, anal canal, breast, head
and neck, esophagus, and lung. Image guidance for
brachytherapy alone is applied also in prostate, liver,
and eye tumors.
7. Quantitative imaging for response-
adaptive radiation oncology
Increasing availability of modern functional imaging
techniques, such as MRI or PET, allows for precise
anatomical, functional, and biological characterization
of tumors before and during RT treatments. With these
modern imaging techniques, it is possible to assess indi-
vidual response to RT already in an early phase of treat-
ment, several weeks before the end of therapy. Modern
RT equipment permits individually modifying the treat-
ment according to the information about individual
response Fig. 7A. Consequently, response-adaptive RT
(ART) is defined as ‘a radiation treatment process where
the treatment plan can be modified using a systematic
feedback of measurements (treatment position variation
due to beam displacement and target geometric varia-
tion)’ [112]. Information about response to RT, such as
tumor volume reduction or characteristic changes in
functional or biological markers of tumor aggressive-
ness, can be optimally assessed using modern imaging
techniques [113]. Triggered by individual response mea-
sures, image-guided adaptive RT provides the technical
basis to achieve optimal cure rates for patients and at
the same time keep the risk for treatment-related side
effects as low as possible.
Clinical trials involving large numbers of patients
suffering from cervical cancer have shown the effec-
tiveness of adaptive RT taking into account tumor
shrinkage at the end of initial chemoradiation, with a
risk-adapted radiation dose prescription to different
tumor regions, and adaptation of the treatment tech-
nique according to individual response and adjacent
OAR [88]. Further evidence of improved treatment
results has been generated by large controlled trials on
adaptive RT in NSCLC patients [114]. The results pro-
vided by these studies demonstrated a high clinical
impact of ART as adjusting the radiation treatment
plan according to changes in the anatomical situation
guarantees maintained or even increased radiation
dose levels in the tumor region while reducing treat-
ment-related toxicities [114–116]. Also in head-and-
neck cancer patients, several smaller trials have proven
the benefit of ART in terms of increasing the thera-
peutic ratio by increasing the radiation dose to the
tumor in a calculable way and therefore sparing adja-
cent normal tissues [117].
Recent clinical trials have shown not only that
changes in the anatomical situation observed during
treatment should be considered during RT, but also
that changes in functional and biological tumor char-
acteristics need to be taken into account for ART.
Several studies have shown that information provided
by PET imaging and functional MRI reveal informa-
tion about the individual aggressiveness of individual
tumors and are prognostic for RT outcome [118–121].
Moreover, clinical trials have shown that characteristic
changes in tumor hypoxia assessed with PET during
the first 2 weeks of RT are associated with treatment
outcome [122,123]. Thus, ART taking into account
functional information obtained during image guid-
ance can help overcome biology-induced radiation
resistance by increasing the radiation dose at resistant
regions inside the tumor (dose painting, Fig. 7B. A
similar concept is investigated in a currently running
trial in head-and-neck cancer patients where radiation
dose to lymph node metastases is de-escalated upon
early response in PET imaging. This might result in
less toxicity without jeopardizing safety [49].
While there is an increasing number of studies inves-
tigating the association between functional imaging
biomarkers and individual response to RT [44,119–
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122,124–126], there is a wide variability in the method-
ology of acquisition and data analysis with respect to
functional imaging. To improve consistency between
studies, quantitative imaging techniques need to be
applied for the assessment of functional tumor charac-
teristics. Quantitative imaging is defined as the extrac-
tion of quantifiable measures from medical images for
the assessment of physiological quantities with respect
to tumor or tissue characterization. As functional
imaging data have a direct impact on the radiation
dose used to treat the patient, quantitative imaging
techniques are a major prerequisite for image-guided
radiation oncology [127].
Current RT techniques, using, for example, the
MRI-Linac, allow for highest geometric precision due
to real-time image guidance [37,42,45,128–131].
In addition, with the clinical availability of online
MRI-guided RT as described above, it is possible to
acquire quantitative MRI data at the time of RT treat-
ment and adapt the treatment according to functional
response measures in real-time [132]. Consequently, quan-
titative imaging-based ART is a modern, high-precision
RT solution, which empowers better cancer cure rates
and at the same time reduces the risk for side effects.
8. The challenge of IGRT technology
assessment
Image-guided radiotherapy is driven by biological con-
cepts, clinical need, and technology developments. The
combination of these three main factors in addition to
the short innovation cycles results in a major challenge
Fig. 7. (A) Schematic representation of different putative adaptation measures, subsequent adaptation measures, and resulting therapeutic
consequences. (B) Illustration of a ART workflow: Before the start of treatment, an optimal treatment plan is generated. During treatment,
systematic feedback measurements about tumor response are taken into account in order to adapt RT in terms of field size, target, or
radiation dose level to yield most optimal therapeutic results.
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for radiation oncology. First of all as in all other areas
of radiation oncology, before a new type of IGRT is
deployed in patients, a rigorous testing and evaluation
are mandatory to ensure patient safety. A new biologi-
cal concept such as dose painting, where imaging is
the enabler to change the dose distribution within
tumors, needs prospective clinical trials including ulti-
mately a comparative randomized phase 3 trial. A new
IGRT technology that is transforming radiation oncol-
ogy such as MR-linacs requires a comprehensive
framework as described in the R-IDEAL concept [36].
Stepwise clinical trials toward comparative randomized
trials are the gold standard of evidence-based medi-
cine. The conduct of these trials in the context of
IGRT is challenged by the high costs, conceptual con-
troversies in the design of health technology assess-
ment trials (e.g., [133], and the contrast between short
innovation cycles and long-term clinical endpoints.
The latter may make data obsolete at the time they
become available to the public because clinical and
technological standards have been changed during the
follow-up period of a trial. In addition, not all patients
even with the same type of cancer will benefit from
new IGRT technology. To overcome this problem,
model-based approaches have been introduced in the
assessment of proton therapy in head and neck cancer
[134]. It is generally accepted that prospective observa-
tional studies are sufficient to validate more incremen-
tal steps in the application of existing IGRT
technology. Examples include IGRT [135] and ART
[114] for lung cancer. However, for most of the inno-
vations in IGRT clinical trials including phase 3 trials
are essential to demonstrate cost-benefit of the new
technology. To address the above-mentioned chal-
lenges, these clinical trials have to be performed in
academic European and international networks which
need substantial support by funding agencies, universi-
ties, and industry. Only a joint effort of the leading
academic centers will ensure that new technology can
be offered timely for the benefit of every cancer patient
without jeopardizing patient safety or violating the
principles of evidence-based medicine as well as soli-
darity in healthcare systems.
9. Summary
High-resolution IGRT has become a mainstay of mod-
ern RT. In-room medical imaging with portal imaging,
CT, MR, or ultrasound has changed clinical practice,
that is, providing the prerequisite to safely deliver radi-
ation dose. The proven concept that IGRT enables full
tumor coverage with sufficient radiation dose and
sparing normal tissue allows improving the outcome of
many cancer patients belongs to the major contribu-
tions of radiation oncology in cancer medicine. IGRT
will remain a driving force for research and develop-
ment, for example, to create novel types of radiation
treatments. IGRT as a core technology will facilitate
the current shift of paradigm toward personalized radi-
ation oncology: imaging biomarkers for repeated, non-
invasive, point-of-care multiscale molecular tissue
profiling which will guide individualized dose prescrip-
tion and real-time response adaptation embedded in
automatized workflows and digitalized environments.
With its track records and future perspectives, image-
guided radiation oncology will be a cornerstone




 CBCT (cone-beam computed tomography): a
special form of computed tomography which can
be installed on a linear accelerator to enable
IGRT.
 Dose painting: a concept in radiation oncology
which proposes to deliver nonhomogeneous radi-
ation doses according to the radiation sensitivity
and treatment response of parts of the tumor.
Conventional radiotherapy delivers the same
dose to the entire tumor. In dose painting imag-
ing for example with PET is used to visualize
parts of the tumor which are more resistant than
others. These parts are then treated with higher
radiation doses.
 Dual-energy CT: a special form of computed
tomography that uses different sources and ener-
gies.
 Volumetric-modulated arc therapy (VMAT):
Volumetric arc therapy is a special form of
highly conformal intensity-modulated radiother-
apy (IMRT) where the rotating treatment beam
is continuously adapted to cover the tumor and
to spare the normal tissues.
 Stereotactic ablative radiotherapy (SABR): A
treatment concept where a single or few fractions
with large radiation doses intended to ablate all
cancer cells are delivered with high precision
using IGRT. Often used in small tumors or lim-
ited metastases.
 Brachytherapy: A special form of radiotherapy
where a radiations source is permanently or tem-
porarily positioned directly or close to the
tumor.
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 Gross tumor volume (GTV): tumor visible to the
naked eye or visualized with medical imaging.
 Clinical target volume (CTV): space surrounding
the GTV which might contain cancer cells which
have infiltrated adjacent tissues. These cancer
cells are invisible by naked eye or medical imag-
ing. Radiation therapy with curative intent needs
to cover this space in order to inactivate all can-
cer cells.
 Planning treatment volume (PTV): takes uncer-
tainties in the precision of treatment delivery, for
example, motion of the organs during treatment
delivery or uncertainties in patient positioning,
into account. PTV represents a composite of
GTV and CTV plus a safety margin. Radiation
oncologists prescribe the radiation dose typically
to the PTV.
 Oligometastatic disease (OMD): A concept that
proposes a state of limited metastases in the
course of the cancer disease where local therapies
such as SABR might be used.
 Positron Emission Tomography (PET): is a med-
ical imaging modality visualizing metabolism
(e.g., glucose metabolism) or pathophysiological
process (e.g., tumor hypoxia).
 Linear accelerator (Linac): most often used treat-
ment device for external beam radiotherapy.
 Adaptive radiotherapy (ART): a concept in radi-
ation oncology which takes the changes of the
tumor during beam delivery (e.g., motion) and
during the course of fractionated radiotherapy
(e.g., tumor shrinkage) into account by adapting
the treatment for example through smaller PTV
or through individualized radiation dose accord-
ing to response.
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